These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26028546)

  • 1. Predicting placebo response in adolescents with major depressive disorder: The Adolescent Placebo Impact Composite Score (APICS).
    Nakonezny PA; Mayes TL; Byerly MJ; Emslie GJ
    J Psychiatr Res; 2015 Sep; 68():346-53. PubMed ID: 26028546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.
    DelBello MP; Hochadel TJ; Portland KB; Azzaro AJ; Katic A; Khan A; Emslie G
    J Child Adolesc Psychopharmacol; 2014 Aug; 24(6):311-7. PubMed ID: 24955812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials.
    Gomeni R; Merlo-Pich E
    Br J Clin Pharmacol; 2007 May; 63(5):595-613. PubMed ID: 17488364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of placebo response in randomized controlled trials of psychotropic drugs for children and adolescents with internalizing disorders.
    Cohen D; Consoli A; Bodeau N; Purper-Ouakil D; Deniau E; Guile JM; Donnelly C
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):39-47. PubMed ID: 20166795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Fish Oil Monotherapy on Depression and Prefrontal Neurochemistry in Adolescents at High Risk for Bipolar I Disorder: A 12-Week Placebo-Controlled Proton Magnetic Resonance Spectroscopy Trial.
    McNamara RK; Strawn JR; Tallman MJ; Welge JA; Patino LR; Blom TJ; DelBello MP
    J Child Adolesc Psychopharmacol; 2020 Jun; 30(5):293-305. PubMed ID: 32167792
    [No Abstract]   [Full Text] [Related]  

  • 8. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
    Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
    J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials.
    Pae CU; Patkar AA; Jang S; Portland KB; Jung S; Nelson JC
    CNS Spectr; 2014 Aug; 19(4):324-9. PubMed ID: 24168807
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
    Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
    Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
    J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):34-40. PubMed ID: 18823760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder.
    Bridge JA; Birmaher B; Iyengar S; Barbe RP; Brent DA
    Am J Psychiatry; 2009 Jan; 166(1):42-9. PubMed ID: 19047322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
    Iovieno N; Papakostas GI
    J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale.
    Clayton AH; Campbell BJ; Favit A; Yang Y; Moonsammy G; Piontek CM; Amsterdam JD
    J Clin Psychiatry; 2007 Dec; 68(12):1860-6. PubMed ID: 18162016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a prediction model for the probability of responding to placebo in antidepressant trials: a pooled analysis of individual patient data.
    Shinohara K; Tanaka S; Imai H; Noma H; Maruo K; Cipriani A; Yamawaki S; Furukawa TA
    Evid Based Ment Health; 2019 Feb; 22(1):10-16. PubMed ID: 30665989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.